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Abstract  
 Epithelial ovarian cancer is one of the most common gynecological 
malignancies and the fifth most frequent cause of cancer death in women, 
affecting over 22,000 women annually. Nearly 15,500 affected women die 
from this disease annually, and chemoresistance from the commonly 
prescribed platinum-based drug, carboplatin, is a major contributor to this 
mortality rate. Previous studies have identified genes with CpG islands that 
are methylated and transcriptionally silenced in resistant epithelial ovarian 
cancer patients. One of these genes is GSK3β, an important regulator of 
apoptosis and cell growth in the Wnt pathway. Thus, understanding the role 
of GSK3β suppression in chemoresistance of epithelial ovarian cancer can 
help contribute to more effective treatments for this disease. By performing 
assays of cell growth, viability, and apoptosis, our study examined the 
functional role that GSK3β plays in carboplatin mediated apoptosis. Our 
results suggest that cells with suppressed GSK3β had increased proliferation 
and reduced apoptosis.  We conclude that silenced GSK3β expression might 
therefore contribute to carboplatin resistance seen in tumors and our in vitro 
analysis suggests that GSK3β expression is vital to carboplatin 
chemosensitivity. Future research is required to further investigate the role of 
GSK3β methylation to facilitate the design of potential genome-guided 
treatments for patients with chemoresistant epithelial ovarian cancer. 
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Introduction 
 Oncologists are constantly seeking new, effective treatments for 
epithelial ovarian cancer. The primary pharmacological treatment for this 
disease is a platinum-based drug (typically carboplatin), coupled with a 
taxane-based drug therapy and surgery (Lum et al., 2013; Marchini et al., 
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2012).  However, 25% of these patients present with resistance to the 
platinum-based drug at diagnosis, and most recurrent tumors ultimately 
become resistant (Lum et al., 2013; Marchini et al., 2012). The high 
prevalence of resistant epithelial ovarian tumors warrants the development of 
new methods to effectively reverse chemoresistance toward carboplatin. 
Previous studies have shown that several genes, including the gene GSK3β 
(Glycogen synthase kinase 3 beta), undergo epigenetic changes in epithelial 
ovarian cancer patients. These changes involve methylation, which causes 
suppression of gene expression (Koukoura et al., 2014; Lum et al, 2013; 
Arend et al., 2013). Understanding these epigenetic alterations is important 
to facilitate the design of new genome-guided therapies (Tang et al., 2015; 
Nestheide et al., 2013). Therefore, our study investigated the role of GSK3β 
inhibition in carboplatin chemoresistance of epithelial ovarian cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Heatmap of the differentially methylated genes, showing epigenetic segregation 
between the platinum resistant (Res) and sensitive (Sen) patient groups. Red represents 
genes that are over-expressed and blue are genes that are under-expressed. Each column 
represents a patient and each row represents a gene (Lum, 2013). 
 
 Epithelial ovarian cancer is one of the most lethal gynecological 
malignancies in women in the developed world, affecting over 22,000 
women annually (Brain et al., 2014). Approximately 9 out of 10 ovarian 
tumors are classified as epithelial (Brain et al., 2014). Chemoresistance is 
among the major aforementioned challenges associated with treating this 
malignancy, thereby requiring further understanding of the underlying 
molecular mechanisms of this disease.   
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 Genetic and epigenetic alterations primarily contribute to a tumor’s 
growth, and these alterations can cause resistance to chemotherapeutics 
(Borley & Brown, 2015; Liu, Chan, & Ngan, 2012). Previous studies have 
identified certain genes that are either under-expressed or over-expressed 
differentially in chemoresistant and chemosensitive epithelial ovarian cancer 
patients, as seen in Figure 1 (Borley & Brown, 2015; Earp & Cunningham, 
2015; Lum et al., 2013). DNA methylation is the transfer of a methyl group 
to the carbon-5 position of cytosine (Lum et al., 2013). This is an example of 
an epigenetic alteration, as it regulates the temporal and spatial dynamics of 
a gene and inhibits its expression (Lum et al., 2013). Recently, DNA 
methylation has been shown to be involved in signaling pathways that 
promote tumorigenesis in epithelial ovarian cancer (Borley & Brown, 2015; 
Lum et al., 2013). Previous studies have identified CpG islands—areas 
where cytosine and guanine nucleotides are adjacent to one another—in a 
family of genes that are methylated and suppressed in patients with 
carboplatin resistant epithelial ovarian cancer (Koukoura et al., 2014; Lum et 
al., 2013). Thus, DNA methylation of genes with CpG islands in epithelial 
ovarian cancer cells can be used as a therapeutic target for developing 
treatments for this disease.  
 GSK3β, a gene involved in the regulation of Wnt signaling, cell 
proliferation, and apoptosis (Figure 2), is among the identified genes that is 
methylated and transcriptionally silenced in chemoresistant epithelial ovarian 
cancer cells (Lum et al., 2013; Cole, 2013; Jacobs et al., 2012). This gene is 
an important regulator of apoptosis, a type of genetically programmed cell 
death that complements cell proliferation in normal tissues (Hilliard et al., 
2011). The response of a tumor to a chemotherapeutic agent has been shown 
to be associated with its apoptotic capacity (Janzen et al., 2015; Han et al., 
2013). Thus, GSK3β may contribute to epithelial ovarian cancer cells’ 
response to chemotherapy. In addition, GSK3β plays a major role in the Wnt 
signaling pathway—a signal transduction mechanism consisting 
of transmembrane proteins that transmit signals from the extracellular matrix 
into the cell (Arend et al., 2013; Barbolina, Burkhalter, & Stack, 2011). As 
the Wnt pathway is involved in gene transcription, growth, and apoptosis 
(Arend et al., 2013; Barbolina, Burkhalter, & Stack, 2011), its associated 
genes may be implicated in the epigenetics of epithelial ovarian cancer.  
 The aim of our study was to investigate the effect of GSK3β 
suppression (mimicking DNA methylation) on carboplatin chemoresistance 
in epithelial ovarian cancer cells. We hypothesized that the inhibition of 
GSK3β expression would suppress drug-induced apoptosis and promote 
proliferation, thereby causing carboplatin chemoresistance. Our in vitro 
findings may help elucidate the role GSK3β expression plays in 
chemosensitivity and the relevance of epigenetic regulation to resistant 
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epithelial ovarian cancer. Collectively, our results can be used as tools to 
develop an individualized, genome-guided treatment for epithelial ovarian 
cancer. 
 
 
 
 
 
 
 
 
 
Figure 2: The pathway of GSK3β and its role in regulating cell proliferation, differentiation, 
and survival (Cole, 2013). 
 
 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell culture and microscopic visualizations 
 Human ovarian surface epithelium (HOSE) 6-3 cell line was utilized, 
which is characterized as sensitive to carboplatin therapy (Lum et al., 2013). 
The cells were treated with either carboplatin alone (the current platinum-
based drug, 200µg/mL) or LiCl (2.5mM) followed by carboplatin. LiCl acts 
to suppress GSK3β gene expression (Nakada et al., 2011; Grassilli et al., 
2013). Throughout the paper, whenever suppression of GSK3β is referred to, 
this indicates that the cells were pretreated with LiCl. Therefore, cells 
pretreated with LiCl did not express GSK3β, whereas the cells not pretreated 
expressed GSK3β. All cells were supplemented with 10-12% fetal bovine 
serum, 2% penicillin-streptomycin, and grown at 37°C with 5% CO2. We 
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took images of cells after two days of incubation using a fluorescence 
microscope (200X), a fluorescein filter, and a fluorescent dye (Figure 3). 
 
Neutral red dye assay  
 We conducted the Neutral Red Dye assay with the “In Vitro 
Toxicology Assay Kit, Neutral Red Dye Based” (Sigma, Product Code 
1002017798) to examine the viability of epithelial ovarian cancer cells. This 
assay determines the accumulation of the red eurhodin dye (toluylene red) in 
the lysosomes of viable cells, and thus more absorbance directly correlates 
with more viability (In vitro toxicology assay kit neutral red based). The 
cells were studied in six groups: 1) untreated; 2) treated with LiCl (to 
suppress GSK3β); 3) treated with carboplatin; 4) treated with 
carboplatin+LiCl; 5) treated with doxorubicin (another chemotherapeutic, 
serving as a comparison); 6) treated with doxorubicin+LiCl. Cells were then 
split into 96-well plates and incubated for 2 hours with Neutral Red Solution 
(10 μL). Following the protocol, we removed the red dye from the wells and 
washed the cells with Neutral Red Assay Fixative (100 μL). After removing 
the Neutral Red Assay Fixative, we added the Neutral Red Assay 
Solubilization Solution (100 μL). The 96-well plate was placed on a shaker 
for ten minutes to complete dissolution. We recorded absorbance at a 
wavelength of the standard 540nm using the BD Gen 5.1 microplate 
colorimetric spectrometer. 
 
Vybrant® MTT Cell Assay 
 We performed the Vybrant® MTT Cell Assay, using the Vybrant® 
MTT Cell Assay Kit (ThermoFisher V-13154) to assess the amount of non-
viable cells with the treatment groups described in the previous section. The 
cleavage and conversion of the soluble yellow dye to the insoluble purple 
formazan is used as a measurement of dead cells (Vybrant® MTT cell assay 
kit). Following the Vybrant® MTT Cell protocol, a 12 mM MTT stock 
solution [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was 
prepared by adding 1 mL of sterile PBS (phosphate-buffered saline) to a 5 
mg vial of MTT. The sample was vortexed until dissolved, 10 mL of 0.01 M 
HCl was added to one tube containing 1 gram of SDS (sodium dodecyl 
sulfate), and 10 μL of the 12 mM MTT stock solution was added to each 
well. The plate was incubated at 37°C for 4 hours. The sample was read at an 
absorbance of 540 nm using a spectrometer. 
 
Caspase 3 assay 
 We performed the Caspase 3 assay (Abcam, ab39401) using the 
Caspase 3 Assay Kit to assess the extent of apoptosis in the cells of the 
aforementioned treatment groups. Following caspase cleavage, a substrate 
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for luciferase (aminoluciferin) is released, resulting in a luciferase reaction 
and the production of light (Caspase 3 assay kit). The absorbance of 
fluorescent light as measured with the spectrometer directly corresponds to 
apoptosis (Caspase 3 assay kit). The cells from each sample group were 
counted using a hemocytometer and microscope; approximately 1.5 x 106 
cells were aspirated. Cells were suspended in 50 μl of chilled Cell Lysis 
Buffer and incubated at 5°C for ten minutes. Centrifugation at 14,000rpm 
was performed for one minute. We then transferred the supernatant into a 
fresh 1.5 mL tube. Following the Abcam protocol, we added 50 μl of Cell 
Lysis Buffer, 2X reaction buffer, and DTT in the 1.5 mL tube. 
(dithiothreitol) (10 μl). The plate was incubated for two hours. Using a 
spectrophotometer, we measured absorbance at 540nm.  
 
Cell counting  
 A cell suspension was prepared in a balanced salt solution (Hanks' 
Balanced Salts [HBSS], Sigma-Aldrich # H9269). Samples of HOSE 6-3 
cells were either: 1) untreated; 2) treated with carboplatin; 3) treated with 
carboplatin+LiCl; 4) treated with doxorubicin. On the sixth day, we counted 
the total number of cells in each sample per µL using a hemocytometer and a 
light microscope (100X).  
 
Data Analysis 
 All data represented in our study is shown as the averages with 
standard deviation bars of three independent trials per experiment. T-tests 
were conducted in comparison to the untreated group with Microsoft 
Excel®, with p < 0.05 and p < 0.01 for significance.  All experiments were 
repeated three times for accuracy, in replicates of 10, unless otherwise stated. 
 
Results 
Cell Cultures and Microscopic Visualizations 
 The primary goal of our study was to observe how inactivation of 
GSK3β contributes to carboplatin resistance in epithelial ovarian cancer 
cells; thus, we qualitatively observed how GSK3β affects the cells’ response 
to carboplatin. Samples of HOSE 6-3 cells were treated with carboplatin 
(Figure 1A) and carboplatin+LiCl (Figure 2B), independently. Since LiCl is 
known to inhibit GSK3β (Grassilli et al., 2013; Nakada et al., 2011), we 
predicted that the LiCl pretreated cells would show more growth and become 
resistant to carboplatin. According to Figure 3, more growth was observed 
in the carboplatin+LiCl group compared to the carboplatin group alone. This 
observation supports our hypothesis by suggesting that GSK3β expression in 
carboplatin treated epithelial ovarian cancer cells decreased cell growth and 
proliferation (Figure 3A). However, GSK3β inhibition increased cell 
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growth, suggesting that the cells deficient in expressed GSK3β survived 
carboplatin treatment (Figure 3B).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Microscopic visualization (fluorescent microscope, magnified 200X) of HOSE 6-3 
cells A) Cells treated with carboplatin exhibited less growth B) Cells treated with 
carboplatin+ 2.5mM LiCl exhibited more growth  
 
Neutral Red Dye Assay 
 We then proceeded to analyze the viability of HOSE 6-3 cells under 
various treatments with active and silenced GSK3β in order to determine the 
level of chemoresistance through the Neutral Red Dye assay (Figure 4). 
Increased absorption of the red dye indicates increased cell viability. HOSE 
6-3 cells pretreated with LiCl were exposed to carboplatin as the main 
treatment and doxorubicin as an independent control. Another group of cells 
(LiCl untreated) were exposed to carboplatin and doxorubicin (Figure 4). 
Since LiCl inhibits GSK3β, we predicted that the LiCl pretreated cells would 
become resistant to carboplatin (Figure 4). Among the LiCl untreated cells, 
those exposed to carboplatin were less viable (absorbance level: 
0.38nm±0.13nm SD, 540nm, p-value: 1.94 x 10-19) compared to those left 
untreated (absorbance level: 1.21nm±0.12nm SD, 540nm). However, among 
the cells pretreated with LiCl, the ones treated with carboplatin showed 
similar levels of viability (absorbance level: 1.19nm±0.094nm SD, 540nm, 
p-value: 1.25 x 10-19) as the untreated ones. Viability of cells treated with 
doxorubicin remained independent of GSK3β expression. We repeated this 
process in three independent trials, each consisting of 10 replicates (Figure 
4). Each of the three independent trials consistently showed that cells 
expressing GSK3β with carboplatin treatment were less viable (Figure 4). 
However, the cells with suppressed GSK3β were more viable upon 
carboplatin administration, absorbance measured at 540-nm (Figure 4).  
 
 
100 μM 
A B 
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Figure 4: GSK3β determines chemoresistance as a function of viability. Cells treated with 
carboplatin and doxorubicin had lower viability than cells treated with carboplatin+LiCl. 
(Carbo=Carboplatin, Doxo=Doxorubicin). The results represent the mean±SD (n=3) (* 
denotes p <0.05, ** denotes p <0.01) 
 
Vybrant® MTT Cell Assay 
 To further assess the validity of our hypothesis, we determined 
whether active GSK3β affects chemoresistance to carboplatin or doxorubicin 
through the Vybrant® MTT Cell assay. This biochemical assay uses 
fluorescent indicators indicates greater levels of non-viable cells. Samples of 
HOSE 6-3 cells were untreated, treated with LiCl alone, carboplatin, 
carboplatin+LiCl, doxorubicin (comparison), or doxorubicin+LiCl (Figure 
5). We predicted that the cells with GSK3β suppressed would show greater 
cell viability compared to the cells with the active form of GSK3β. 
According to Figure 5, the cells treated with carboplatin and doxorubicin 
(separately) showed the highest absorbance (1.42nm±0.23nm SD and 
1.77nm±0.35nm SD respectively, p-values: 3.9 x 10-6 and 1.9 x 10-9), 
thereby indicating the greatest amounts of non-viable cells. In contrast, the 
cells treated with carboplatin+LiCl had similar amounts of cell viability 
(absorbance level: 0.49nm±0.05nm SD, p-values: 3.2 x 10-5) as the untreated 
groups (absorbance level: 0.48nm±0.13nm SD). Each of the three 
independent trials consistently showed that cells expressing GSK3β with 
carboplatin treatment were not viable. However, cells with suppressed 
GSK3β were viable upon carboplatin administration (Figure 5). 
Additionally, cells treated with doxorubicin+LiCl had a similar absorbance 
(1.52nm±0.13nm SD, p-value: 3.4 x 10-2) as doxorubicin alone 
(1.71nm±0.23nm SD, p-value: 1.9 x 10-9) (Figure 5, 540nm absorbance).   
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Figure 5: GSK3β determines chemoresistance as a function of non-viability. The sample 
treated with carboplatin had many non-viable cells. Cells treated with carboplatin and LiCl 
had a lower amount of non-viable cells, almost identical to that of the untreated cells. 
(Carbo=Carboplatin, Doxo=Doxorubicin). The results represent the mean±SD, n=3. (* 
denotes p <.05, ** denotes p <.01) 
 
Caspase 3 Assay 
 GSK3β plays a pivotal role in regulating apoptosis, and since a 
tumor’s response to chemotherapy has been shown to be correlated with 
apoptotic-induction (Janzen et al., 2015; Han et al., 2013) we sought to 
analyze apoptosis in cell samples with or without expressed GSK3β. To 
achieve this, we performed the Caspase 3 assay. Treatments mirrored the 
groups in the previous protocols (Figure 4 and 5). Figure 6 illustrates that 
the cells treated with carboplatin+LiCl were less apoptotic, compared to cells 
with carboplatin alone. In other words, cells expressing GSK3β were more 
susceptible to carboplatin, thus showing increased apoptosis (absorbance 
levels: 0.69nm±0.12nm SD, p-values-7.0 x 10-8). This is in direct contrast to 
cells that did not express GSK3β and were exposed to carboplatin 
(absorbance level: 0.16nm±0.002nm SD, p-value: 1.9 x 10-2). Figure 6 
shows that GSK3β suppression did not affect the extent of apoptosis under 
doxorubicin treatment but did affect apoptosis under carboplatin treatment. 
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Figure 6: GSK3β determines chemoresistance as a function of apoptosis. Cells treatment 
with carboplatin had much higher levels of apoptosis than untreated. The cells with 
carboplatin and LiCl had very low levels of apoptosis, almost identical to those of the 
untreated cells. (Carbo=Carboplatin, Doxo=Doxorubicin). The results represent the 
mean±SD, n=3. 5 (* denotes p <0.05,     ** denotes p <0.01) 
 
 Cell Counting 
To quantify cell growth and proliferation of the cells with expressed 
and suppressed GSK3β, we performed cell counts on samples of HOSE 6-3 
cells (Figure 7). We had a sample of HOSE 6-3 cells, which were untreated, 
and another sample that was treated with carboplatin, carboplatin+LiCl, and 
doxorubicin (independently); these samples were incubated and counted after 
two days using a hemocytometer and a light microscope (100X). Figure 7 
highlights how there was less growth with doxorubicin. Additionally, cells 
treated with carboplatin+LiCl had similar amounts of growth (1.18 x 106 
cells/µL, p-value: 7.63 x 10-3) as the untreated cells. All results reflect three 
independent trials with 10 replicates each.  However, cells with carboplatin 
alone had significantly less growth (6.2 x 105 cells/µL, p-value: 2.93 x 10-2). 
Thus, GSK3β suppression causes more growth following carboplatin 
exposure. 
  
* 
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Figure 7: GSK3β determines chemoresistance as a function of cell number. Cell Counting 
using a light microscope (100X): Cells with carboplatin+LiCl grew and proliferated at 
almost the same rate as the untreated cells. Cells with carboplatin and doxorubicin grew at a 
much slower rate. Results represent the mean±SD (n=3). (* denotes p <0.05, ** denotes p 
<0.01 compared to untreated) 
 
Conclusion and Discussion 
 Chemoresistance in epithelial ovarian cancer is an important clinical 
issue as it presents a major limitation to effective treatment and addressing 
recurrence. Previously, it has been shown that gene expression differs 
between chemoresistant and chemosensitive epithelial ovarian cancer 
patients (Figure 1) (Borley & Brown, 2015; Lum et al., 2013; Cole, 2013). 
The mechanisms responsible for a tumor’s ability to resist treatment are 
often caused by epigenetic alterations, including gene methylation (Liu, 
Chan, & Ngan, 2012). We investigated GSK3β expression to identify 
potential gene targets for carboplatin resistant epithelial ovarian cancer. 
GSK3β is a major regulator of cell apoptosis and growth in the Wnt pathway 
(Lum et al., 2013; Jacobs et al., 2012). This gene has been shown to be 
methylated and suppressed in epithelial ovarian cancer and has been 
implicated in chemoresistance of other cancers (Grassilli et al., 2013; Lum et 
al., 2013; Jacobs et al., 2012). Thus, we examined the role of GSK3β in 
epithelial ovarian cancer cells that were known to be carboplatin sensitive as 
described by our previous publication (Lum et al., 2013). In our study, we 
assessed cell viability, apoptosis and growth (Figures 3 to 7) in the HOSE 6-
3 cell line, pretreated with LiCl (GSK3β suppressed) or without LiCl 
(GSK3β expressed). LiCl inhibits GSK3β expression through two 
mechanisms: 1) Promoting Ser-9 phosphorylation, an inhibitory marker, and 
2) Blocking Mg2+ ions from binding, thus preventing activation of GSK3β 
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(Grassilli et al., 2013; Nakada et al., 2011).  In the future we plan to further 
elucidate the mechanisms involved in the signal transduction pathway of 
GSK3β in our cell lines. 
 Microscopically visualizing cells under different treatments was 
necessary in studying the role of GSK3β inhibition in cell growth and 
carboplatin chemoresistance (Figure 3). There were fewer viable cells after 
carboplatin exposure in cells without 2.5mM LiCl treatment compared to 
cells with LiCl treatment; this suggests the role of GSK3β expression in cell 
protection and apoptosis (Figure 3). Results from the Neutral Red Dye 
assay, Vybrant® MTT Cell assay, Caspase 3 assay, and direct cell counts 
assays provided further support for our hypothesis (Figure 4 to 6). 
 Analyzing viability of the cells under different treatments was critical 
to studying the role of GSK3β inhibition in chemoresistance. We determined 
overall cell viability with the Neutral Red Dye and Vybrant® MTT Cell 
assays. According to the Neutral Red Dye assay, carboplatin treatment 
significantly decreased cell viability in cells that expressed GSK3β (p-value: 
1.94 x 10-19) (Figure 4). However, in cells with silenced GSK3β, carboplatin 
was not effective in decreasing viability (p-value: 1.25 x 10-19) (Figure 4). 
This suggests that GSK3β is critical to cellular viability, and suppressing its 
expression may result in chemoresistance. Sensitivity to doxorubicin 
remained independent of GSK3β expression, suggesting that GSK3β 
inhibition affects carboplatin resistance, but not doxorubicin resistance. This 
is perhaps because doxorubicin has a different mechanism of action that may 
be GSK3β independent (Thorn et al., 2012).  Future work in our lab 
continues to examine the variable mechanisms of action of both drugs. 
 Next, the Vybrant® MTT Cell assay analyzed cell viability with 
active and silenced GSK3β, treated with carboplatin and doxorubicin, 
independently (Figure 5). Our results show that the untreated cells had 
almost identical amounts of non-viable cells as those treated with 
carboplatin+LiCl (p-value: 3.2 x 10-5); this once again suggests that 
suppressing GSK3β can potentially lead to carboplatin chemoresistance 
(Figure 5), as it resulted in a direct effect on cellular viability. However, the 
HOSE 6-3 cells with expressed GSK3β were significantly less viable upon 
carboplatin exposure, suggesting that the cells were selectively transformed 
upon the addition of LiCl and remained chemosensitive (p-value: 3.9 x 10-6) 
(Figure 5). Additionally, the sample treated with doxorubicin and 
doxorubicin+LiCl independently had similar amounts of non-viable cells, 
suggesting that GSK3β suppression does not affect resistance to doxorubicin.  
Future studies are required to elucidate how the suppression of GSK3β 
results in carboplatin resistance, and how the expression of GSK3β results in 
carboplatin sensitivity by looking at upstream and downstream targets in the 
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Wnt/ β-catenin pathway. Current research in our lab suggests that GSK3β 
acts independently in this role (results not shown). 
 One major path of chemoresistance involves the dysregulation of 
apoptosis. Dysfunctional apoptotic responses may result in uncontrolled cell 
growth, leading to cancer (Han et al., 2013). The efficacy of most 
chemotherapeutics, such as platinum-based drugs, relies heavily on their 
ability to induce apoptosis (Lum et al., 2013). As a consequence, 
chemoresistant cells often have down-regulated pro-apoptotic genes or up-
regulated anti-apoptotic genes (Lum et al., 2013). To determine whether 
GSK3β expression specifically affects apoptosis, the Caspase 3 assay was 
performed (Figure 6). Since GSK3β is involved in regulating apoptosis 
(Lum et al., 2013; Jacobs et al., 2012), we analyzed apoptosis levels in cells 
with various treatments, with or without GSK3β (Figure 6). Carboplatin 
induced a significantly greater level of apoptosis in this cell line (p-value: 7.0 
x 10-8) when compared to untreated cells (Figure 6). These results suggest 
that the cells with active GSK3β continue to undergo apoptosis when treated 
with carboplatin.  In contrast, cells treated with carboplatin+LiCl (p-value: 
1.9 x 10-2), showed no difference in levels of apoptosis compared to 
untreated cells (Figure 6), strongly suggesting that GSK3β suppression plays 
a critical role in modification of carboplatin apoptotic pathways. When 
GSK3β was inhibited in cells treated with doxorubicin (p-value: 4.1 x 10-7), 
the sample showed nearly identical levels apoptosis as the sample with 
GSK3β expressed (p-value: 7.6 x 10-5); this finding suggests that GSK3β 
affects carboplatin apoptotic pathways selectively; this may be because of 
the fact that carboplatin and doxorubicin belong to different classes of drugs; 
carboplatin is classified as an alkylating agent, whereas doxorubicin is an 
anthracycline antibiotic (Thorn et al., 2012). Thus, GSK3β may regulate 
carboplatin chemosensitivity because it is associated with the same apoptotic 
pathway that carboplatin induces. Doxorubicin has a different mechanism of 
action that we predict is GSK3β independent (Thorn et al., 2012). Figure 6 
highlights the expression of GSK3β as a determinant for carboplatin-induced 
apoptosis among HOSE 6-3 cells. These results demonstrate that the 
inhibition of GSK3β reduces carboplatin-induced apoptosis, which may be 
responsible for chemoresistance as observed in clinical cases (Conic et al., 
2015; Lum et al., 2013).  We have seen the same modification of apoptosis 
in our lab using cisplatin, another alkylating agent with similar properties to 
carboplatin, suggesting GSK3β plays a selective role in platinum based 
apoptotic pathway signaling (results not shown).  Platinum based drugs have 
the ability to add alkyl groups to many electronegative groups, thereby cross-
linking strands of DNA (Sharon et al., 2009). 
 Cell growth was assessed directly through cell count (Figure 7). 
There was significantly less cell growth with doxorubicin (p-value: 3.89 x 
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10-2). There was less cell growth with carboplatin as well (p-value: 2.93 x 10-
2). However, there was significantly more cell growth when the sample was 
pretreated with LiCl followed by carboplatin (p-value: 7.63 x 10-3) (Figure 
7). Collectively, our results support our other studies (Lum et al., 2013) and 
demonstrate that suppression of GSK3β leads to modification of cellular 
viability by increasing cellular growth when GSK3β is silenced.  
Importantly, our results suggest that this change in cellular viability can 
result in chemoresistance, and expression of GSK3β leads to carboplatin 
chemosensitivity. 
 Epithelial ovarian cancer is one of the deadliest gynecological 
malignancies that affects women worldwide (Liu, Chan, & Ngan, 2013). 
Evidence from previous studies shows that genetic and epigenetic alterations 
are major underlying mechanisms that contribute to tumorigenesis, 
especially in epithelial ovarian cancer (Borley & Brown, 2015; Liu, Chan, & 
Ngan, 2013). Chemoresistance to the current platinum-based therapy in such 
cases is a major obstacle for the clinical management of epithelial ovarian 
cancer (Borley & Brown, 2015; Liu, Chan, & Ngan, 2012). Thus, developing 
a treatment that prevents or reverses chemoresistance is vital for the survival 
of epithelial ovarian cancer patients. To overcome this challenge, it is 
important to study genes involved in epithelial ovarian cancer. Recent 
studies have identified genes with CpG islands that undergo epigenetic 
alterations, particularly methylation, and are associated with the acquisition 
of chemoresistance in epithelial ovarian cancer (Koukoura et al., 2014; Lum 
et al., 2013; Zeller et al., 2011). Specifically, GSK3β is a gene with CpG 
islands that has been shown to be transcriptionally silenced via methylation 
in resistant epithelial ovarian cancer patients (Lum et al., 2013; Jacobs et al., 
2012). Therefore, our study focused on GSK3β and its relation to carboplatin 
chemoresistance in epithelial ovarian cancer. By performing various assays 
of cell growth, viability, and apoptosis, our study successfully supported our 
hypothesis by demonstrating that GSK3β suppression results in tumorigenic 
properties and carboplatin chemoresistance (Figures 3 to 7). These results 
strongly suggest that GSK3β expression plays a significant (p < 0.05 or p < 
0.01) role in carboplatin sensitivity, supporting previous studies that have 
been done involving other genes with chemoresistant epithelial ovarian 
cancer (Lum et al., 2013). In the future, therapies can be developed that 
target GSK3β and the Wnt pathway. These findings hold promise for future 
genome-guided chemotherapy based on a patient’s individual gene 
expression profile (Tang et al., 2015; Nestheide et al., 2013).  
 Another approach we propose is to target other downstream effectors 
of GSK3β in the Wnt signaling pathway, such as β-catenin (Figure 2). 
Currently this is an active area of research in our lab.  Additionally, our 
recent research suggests that blocking methylation with a demethylating 
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enzyme can reverse carboplatin chemoresistance (Cheishvili et al., 2015). 
However, it is difficult to solely block methylation of a single gene in vivo 
without disrupting other normal epigenetic processes (Handy, Castro, & 
Loscalzo, 2012). Hence, we can use our data and explore the Wnt/β-catenin 
pathway to create a more targeted treatment. Figure 2 suggests that 
inhibiting this gene via methylation would inhibit downstream effectors of 
GSK3β, such as β-catenin, resulting in uncontrolled proliferation and 
tumorigenic properties (Arend et al., 2013; Cole, 2013). Thus, we suggest 
that activating these downstream effectors, such as β-catenin, would be 
effective in circumventing this process and blocking proliferation signaling. 
Additional studies in upregulating β-catenin are necessary to examine the 
efficacy of this approach.  We plan to actively research this in the future. 
 Our study demonstrates that the inhibition of GSK3β plays a major 
role in carboplatin chemoresistance of epithelial ovarian cancer, and its gene 
expression promotes carboplatin sensitivity. Studying the role of epigenetics 
and methylated genes, such as GSK3β, in chemoresistance of epithelial 
ovarian cancer can lead to increased accuracy in diagnosis, prognosis, and 
treatment of this disease. All the above-stated investigations could improve 
treatment efficacy, reduce the need for more aggressive treatment modalities, 
and facilitate the development of specific genome-guided therapy that target 
resistant epithelial ovarian tumors. 
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